重组人生长激素对特发性矮小症患儿血清Ghrelin及胰岛素样生长因子-1水平的影响

Effect of recombinant human growth hormone on serum Ghrelin and IGF-1 levels in children with idiopathic short stature

摘要:

目的 探究重组人生长激素（rHGH）联合小剂量司坦唑醇对特发性矮小症（SS）患儿血清食欲刺激素（Ghrelin）及胰岛素样生长因子-1（IGF-1）水平的影响。方法 选取2013年12月—2015年6月接受治疗的特发性SS患儿120例，按照随机数字表法分为对照组和观察组，每组60例。对照组患者使用小剂量司坦唑醇治疗，观察组患者在对照组基础上联合使用rHGH进行治疗。对比两组患者治疗前后生长速度（GV）、骨龄（BA）、预测成年身高（PAH），检测并比较两组Ghrelin、IGF-1水平变化情况。结果 观察组治疗6、12及18个月后GV、PAH升高，并高于对照组（P?<0.05）。两组治疗后血清Ghrelin、IGF-1水平均改善，其中观察组Ghrelin水平低于对照组（P?<0.05），IGF-1水平高于对照组（P?<0.05）。结论 rHGH联合常规治疗可更有效地治疗小儿特发性SS，其机制可能与rHGH具有调节Ghrelin、IGF-1水平，从而提高代谢并促进细胞生长有关。

Abstract:

Objective To investigate the levels of serum appetite stimulating hormone (Ghrelin) and insulin-like growth factor-1 (IGF-1) in children with idiopathic short stature (SS) by recombinant human growth hormone (rHGH) combined with low-dose Stanozolol. Methods A total of 120 ISS children treated from December 2013 to June 2015 were selected and divided into control group and observation group according to the digital random table method. Patients in the control group were treated with low dose Stanozolol. And patients in the observation group were treated with rHGH in combination with the control group. The growth rate (GV), bone age (BA), and predicted adult height (PAH) were compared between the two groups. The changes of Ghrelin and IGF-1 levels were detected and compared. Results GV and PAH increased in the observation group after 6, 12 and 18 months, and were higher than those in the control group (P?